OBJECTIVE: To determine factors that may modify the association between hormone therapy (HT) and breast cancer risk. DESIGN: Prospective cohort study (the Melbourne Collaborative Cohort Study) of 24,479 women aged 40 to 69 years. History of HT use was collected at baseline and 4 years later by questionnaire. By June 2002, 336 cases of breast cancer were diagnosed among 13,444 women postmenopausal at baseline. Association of breast cancer risk with history of HT use was analyzed using proportional hazards models. RESULTS: The hazard ratio (HR) for recent HT use (current or stopped within the last year) was elevated (HR 1.51; 95% CI, 1.16-1.98) but was not significantly increased for past HT users (HR 1.19; 95% CI, 0.86-1.64). Recent HT use was associated with better differentiated tumors but was not more likely to be associated with estrogen receptor-positive / progesterone receptor-positive tumors. There was little evidence of interactions between recent HT use and body mass index, alcohol intake, parity, and smoking, although the HR for recent HT use in categories of alcohol consumption was greatest in women consuming the most alcohol (HR 2.37; 95% CI, 1.45-3.88 for those consuming > or = 10 g/d versus HR 1.33; 95% CI, 0.85-2.08 for nondrinkers, P interaction = 0.32). CONCLUSIONS: The risk of breast cancer for recent users of HT in this Australian population is increased by approximately 50%. Our results suggest that any potential modifying effect of the association between HT and breast cancer risk by factors such as alcohol intake and body mass index is likely to be modest.
OBJECTIVE: To determine factors that may modify the association between hormone therapy (HT) and breast cancer risk. DESIGN: Prospective cohort study (the Melbourne Collaborative Cohort Study) of 24,479 women aged 40 to 69 years. History of HT use was collected at baseline and 4 years later by questionnaire. By June 2002, 336 cases of breast cancer were diagnosed among 13,444 women postmenopausal at baseline. Association of breast cancer risk with history of HT use was analyzed using proportional hazards models. RESULTS: The hazard ratio (HR) for recent HT use (current or stopped within the last year) was elevated (HR 1.51; 95% CI, 1.16-1.98) but was not significantly increased for past HT users (HR 1.19; 95% CI, 0.86-1.64). Recent HT use was associated with better differentiated tumors but was not more likely to be associated with estrogen receptor-positive / progesterone receptor-positive tumors. There was little evidence of interactions between recent HT use and body mass index, alcohol intake, parity, and smoking, although the HR for recent HT use in categories of alcohol consumption was greatest in women consuming the most alcohol (HR 2.37; 95% CI, 1.45-3.88 for those consuming > or = 10 g/d versus HR 1.33; 95% CI, 0.85-2.08 for nondrinkers, P interaction = 0.32). CONCLUSIONS: The risk of breast cancer for recent users of HT in this Australian population is increased by approximately 50%. Our results suggest that any potential modifying effect of the association between HT and breast cancer risk by factors such as alcohol intake and body mass index is likely to be modest.
Authors: Hazel B Nichols; Minouk J Schoemaker; Lauren B Wright; Craig McGowan; Mark N Brook; Kathleen M McClain; Michael E Jones; Hans-Olov Adami; Claudia Agnoli; Laura Baglietto; Leslie Bernstein; Kimberly A Bertrand; William J Blot; Marie-Christine Boutron-Ruault; Lesley Butler; Yu Chen; Michele M Doody; Laure Dossus; A Heather Eliassen; Graham G Giles; Inger T Gram; Susan E Hankinson; Judy Hoffman-Bolton; Rudolf Kaaks; Timothy J Key; Victoria A Kirsh; Cari M Kitahara; Woon-Puay Koh; Susanna C Larsson; Eiliv Lund; Huiyan Ma; Melissa A Merritt; Roger L Milne; Carmen Navarro; Kim Overvad; Kotaro Ozasa; Julie R Palmer; Petra H Peeters; Elio Riboli; Thomas E Rohan; Atsuko Sadakane; Malin Sund; Rulla M Tamimi; Antonia Trichopoulou; Lars Vatten; Kala Visvanathan; Elisabete Weiderpass; Walter C Willett; Alicja Wolk; Anne Zeleniuch-Jacquotte; Wei Zheng; Dale P Sandler; Anthony J Swerdlow Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-06-09 Impact factor: 4.254
Authors: Susan J Jordan; Louise F Wilson; Christina M Nagle; Adele C Green; Catherine M Olsen; Christopher J Bain; Nirmala Pandeya; David C Whiteman; Penelope M Webb Journal: Aust N Z J Public Health Date: 2015-10 Impact factor: 2.939
Authors: Xiaoliang Wang; Pooja Middha Kapoor; Paul L Auer; Joe Dennis; Alison M Dunning; Qin Wang; Michael Lush; Kyriaki Michailidou; Manjeet K Bolla; Kristan J Aronson; Rachel A Murphy; Angela Brooks-Wilson; Derrick G Lee; Emilie Cordina-Duverger; Pascal Guénel; Thérèse Truong; Claire Mulot; Lauren R Teras; Alpa V Patel; Laure Dossus; Rudolf Kaaks; Reiner Hoppe; Wing-Yee Lo; Thomas Brüning; Ute Hamann; Kamila Czene; Marike Gabrielson; Per Hall; Mikael Eriksson; Audrey Jung; Heiko Becher; Fergus J Couch; Nicole L Larson; Janet E Olson; Kathryn J Ruddy; Graham G Giles; Robert J MacInnis; Melissa C Southey; Loic Le Marchand; Lynne R Wilkens; Christopher A Haiman; Håkan Olsson; Annelie Augustinsson; Ute Krüger; Philippe Wagner; Christopher Scott; Stacey J Winham; Celine M Vachon; Charles M Perou; Andrew F Olshan; Melissa A Troester; David J Hunter; Heather A Eliassen; Rulla M Tamimi; Kristen Brantley; Irene L Andrulis; Jonine Figueroa; Stephen J Chanock; Thomas U Ahearn; Montserrat García-Closas; Gareth D Evans; William G Newman; Elke M van Veen; Anthony Howell; Alicja Wolk; Niclas Håkansson; Hoda Anton-Culver; Argyrios Ziogas; Michael E Jones; Nick Orr; Minouk J Schoemaker; Anthony J Swerdlow; Cari M Kitahara; Martha Linet; Ross L Prentice; Douglas F Easton; Roger L Milne; Peter Kraft; Jenny Chang-Claude; Sara Lindström Journal: Sci Rep Date: 2022-04-13 Impact factor: 4.996